PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Refractory Solid Tumors · Relapsed Solid Tumors · Relapsed Neuroblastoma · Refractory Neuroblastoma · Relapsed Rhabdomyosarcoma · Refractory Rhabdomyosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Cedars-Sinai Medical Center, Los Angeles, California, United States

    Contact: Principal Investigator (Leo Mascarhenhas, MD)
  • University of California, San Francisco, San Francisco, California, United States

    Contact: Principal Investigator (Jennifer Michlitsch, MD)
  • Boston Children's Hospital, Boston, Massachusetts, United States

    Contact: Principal Investigator (David Shulman, MD)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Principal Investigator (David Shulman, MD)
  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Meghan Donnelly, MPH) · donnellymt@chop.edu · 267-426-9343
    Contact: Principal Investigator (Jacquelyn Crane, MD)
  • Texas Children's Hospital, Houston, Texas, United States

    Contact: Principal Investigator (Jennifer Foster, MD)
  • University of Utah Hospital, Salt Lake City, Utah, United States

    Contact: Principal Investigator (Matthew Dietz, MD)
Study leads
  • Jacquelyn Crane, MD

    Principal Investigator

    Children's Hospital of Philadelphia